Fabomotizole

Fabomotizole
Clinical data
Trade names	Afobazole
Other names	Obenoxazine
Routes of; administration	Oral
Legal status
Legal status	US: Unscheduled Not FDA approved;
Pharmacokinetic data
Bioavailability	43.64%, pronounced first-pass effect
Metabolism	extensive hepatic
Onset of action	0.85±0.13 hours
Elimination half-life	0.82±0.54 hours
Identifiers
	IUPAC name 4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine;
CAS Number	173352-21-1;
PubChem CID	9862937;
DrugBank	DB13623;
ChemSpider	8038633;
UNII	0F8K1X115C;
KEGG	D10561;
ChEBI	CHEBI:135309;
ChEMBL	ChEMBL3707307;
CompTox Dashboard (EPA)	DTXSID00169606 ;
Chemical and physical data
Formula	C15H21N3O2S
Molar mass	307.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOc3ccc2nc(SCCN1CCOCC1)[nH]c2c3;
	InChI InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17) ; Key:WWNUCVSRRUDYPP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fabomotizole (INN;^[1] brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.^{[citation needed]} Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors.^[2]^[3]^[4]^[5]^[6] Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.^[7]

Quick facts Clinical data, Trade names ...

Experiments in mice have shown antimutagenic and antiteratogenic properties.^[8]

Experiments in rats have shown beneficial effect in the model of ischemic stroke.^[9]

Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.

See also